Gal-1 monoclonal antibody enhances cytotoxicity of γδT cells against cervical carcinoma cells
Article
Figures
Metrics
Preview PDF
Reference
Related
Cited by
Materials
Abstract:
Objective:To investigate the cytotoxicity of γδT cells combined with galectin-1 (Gal-1) monoclonal antibody against human cervical carcinoma cells. Methods: γδT cells were expanded in vitro using the solid-phase antibody coated method from tumor infiltrating lymphocyte (TILs) of the human cervical cancer specimens. The purity of γδT cells was measured by flow cytometry. The expressions of Gal-1 in cervical carcinoma SiHa and HeLa cells and in cell supernatants were detected by Western blotting and ELISA, respectively. The cytotoxicity of γδT cells combined with Gal-1 mAb against the human cervical cancer SiHa and HeLa cells was measured by lactate dehydrogenase (LDH) release assay. Tumor-bearing mouse model was established by subcutaneous injection of SiHa cells. Tumor-bearing mice were randomly divided into a control group (SiHa group), an isotype control group (SiHa+mouse IgG1 group), a γδT cell group (SiHa+γδT group), a Gal-1 mAb group (SiHa+γδT+Gal-1 mAb group) and a γδT cell + Gal-1 mAb group (γδT cell+Gal-1 mAb group). The tumor growth was observed in different groups. Results: The percentage of TCRγδ positive T cells expanded using the solid-phase antibody coated method in vitro was (91.2±1.2) %. Gal-1 was over-expressed in SiHa, HeLa cells and cell supernatants. Compared with the control group, the Gal-1 mAb group showed an increasing cytotoxicity efficiency on SiHa cells (\[68.1±3.0\] % vs \[48.7±3.8\]%, P<005) and HeLa cells (\[79.4±5.6\]% vs \[48.3±6.5\]%, P<0.05). The volume of implanted tumors in the γδT +Gal-1 mAb group was significantly smaller than that in the Gal-1 mAb group (\[31.3±9.1\] vs \[199.6±41.2\] mm3, P<0.01) and the γδT cell group (\[31.3±9.1\] vs \[85.6±45.1\] mm3, P<0.05) 30 days after tumor implantation in nude mice. Conclusion: Gal-1 mAb antibody can boost up the cytotoxicity of γδT cells against the human cervical carcinoma cells.
Keywords:
Project Supported:
Project supported by the Scientific Foundation for Distinguished Young Scholars of Hubei Province (No. 2008CDB126), and the Start Project for Talents in Wuhan University of Science and Technology (No. 530033)